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The immune response following neuroinflammation is a vital element of ischemic stroke
pathophysiology. After the onset of ischemic stroke, a specialized vasculature system
that effectively protects central nervous system tissues from the invasion of blood
cells and other macromolecules is broken down within minutes, thereby triggering the
inflammation cascade, including the infiltration of peripheral blood leukocytes. In this
series of processes, blood-derived monocytes have a significant effect on the outcome
of ischemic stroke through neuroinflammatory responses. As neuroinflammation is a
necessary and pivotal component of the reparative process after ischemic stroke,
understanding the role of infiltrating monocytes in the modulation of inflammatory
responses may offer a great opportunity to explore new therapies for ischemic stroke. In
this review, we discuss and highlight the function and involvement of monocytes in the
brain after ischemic injury, as well as their impact on tissue damage and repair.
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INTRODUCTION
Stroke is the third leading cause of death globally, and ∼80% of all strokes are ischemic strokes,
which occur when brain cells die of reduced blood supply to various parts of the brain (1–3).
Within minutes after the onset of stroke, immune processes are activated by ischemic cascades,
from intravascular events triggered by the occlusion and moving of vessels to brain parenchymal
inflammatory responses, leading to tissue damage and repair (4–10). The pathophysiological
features of ischemic stroke, such as the production of reactive oxygen species (ROS) (11), the
release of ATP and UTP by dying cells (12), and the loss of beneficial nitric oxide (NO) in
states of oxidative stress (13), can trigger the activation of a neuroinflammatory response (14–17).
In addition, cells that are dying of a lack of blood supply release cytokines, chemokines, and
matrix metalloproteinases, thereby inducing the infiltration of blood cells, such as monocytes,
lymphocytes, neutrophils, and natural killer cells, into the injured brain parenchyma (18–20). The
initial immune response to neuroinflammation following ischemic stroke is characterized by early
neutrophils swarming into the ischemic injured brain. Neutrophils’ immune process has been
extensively studied and is well-organized, with subsequent steps of cellular recruitment (21–25).
However, little is known about the impact of monocyte recruitment to brain tissue affected by
ischemic injury.
In mice, monocytes are categorized into two functional subpopulations, which can be
differentiated by the expression of specific surface markers, such as lymphocyte antigen 6C (Ly6C),
C-C chemokine receptor 2 (CCR2), and CX3C chemokine receptor (CX3CR1) (26). The first
Park et al. Monocyte Transmodulation for Ischemic Stroke
subset is characterized as short-lived and pro-inflammatory, with
active recruitment to inflamed tissues by circulating through the
blood; this subpopulation expresses Ly6C+CCR2highCX3CR1low
markers (27). The second subset is known for alternative and
non-classical activation, and it is characterized by an anti-
inflammatory phenotype and CX3CR1-dependent recruitment
to local non-inflamed tissues; this subpopulation expresses
Ly6C−CCR2lowCX3CR1high markers (28–30). Blood monocytes
have plasticity and are embroiled in pro-inflammatory and anti-
inflammatory responses in various diseases (28, 31–34). Blood
monocytes are a heterogeneous population of circulating
leukocytes. The classical pro-inflammatory monocytes
(Ly6C+CCR2highCX3CR1low) are rapidly recruited to inflamed
tissues and release high levels of inflammatory cytokines,
such as tumor necrosis factor-α (TNF-α) (35), interleukin-1
β (IL-1β) (36), and IL-6 (37), when there is tissue damage.
Further, these monocytes may turn into tissue macrophages
(38). On the contrary, the alternative non-classical monocytes
(Ly6C−CCR2lowCX3CR1high) play a crucial role in reparative
processes, producing anti-inflammatory cytokines, such as IL-4,
IL-10 (39), and IL-13 (40), in inflammatory environments.
Alternative monocytes can also turn into alternative
macrophages (41–44). These two distinct subsets of monocytes
are known to be polarized into M1 (pro-inflammatory) (45) or
M2 (anti-inflammatory) (46) macrophages, thereby influencing
the local milieu at different time points following tissue
damage (47–49).
Given that the immune response comprises numerous
cell populations that influence the neuroinflammatory
process at different times, detailed analytical studies
of infiltrating monocytes are needed. In this review,
we summarize the precise roles of infiltrating blood
monocytes on neuroinflammation following ischemic
stroke, highlighting how the distinct subsets of monocytes
work in beneficial and noxious ways. Efforts to understand
the mechanisms of monocytes in neuroinflammation
following ischemic stroke may not only help address the
limitations of current stroke therapies, but also suggest novel
treatment strategies for stroke through the modulation of
immune cells.
DEVELOPMENT AND MIGRATION OF
MONOCYTES
Monocytes are distinct myeloid components of an organism’s
innate immune system, and they are heavily involved
in organisms’ neuropathological processes (50, 51). The
development of classical Ly6C+ monocytes begins when they
are derived from hematopoietic stem cells (HSCs) in the bone
marrow (BM); depending on the macrophage colony-stimulating
factor (M-CSF), the development of blood monocytes may vary
(52, 53). Once Ly6C+ monocytes egress in the blood, they
are considered incompletely differentiated cells, which have
a high degree of developmental plasticity (54). These highly
adjustable monocytes differentiate into phagocytic macrophages
as they promptly drift toward inflamed tissues after sensing
environmental stimuli following injury (55–57). In addition, in
a steady state, circulating Ly6C+ pro-inflammatory monocytes
are the precursors of the Ly6C− monocytes patrolling the
vasculature in the blood and BM (58). Furthermore, the
differentiation and development of monocyte subpopulations
are affected by numerous factors, including Kruppel-like factor 4
(KLF4) (59). Alder et al. investigated the consequences of KLF4
function loss for monocytes; the producibility of CD115+Gr+
monocytes, the Ly6C+ monocytes, was thoroughly reduced by
the transplantation of KLF−/− fetal liver cells into wild-type
mice, which were subjected to lethal irradiation (59). CCR2
(60) and its agonists, monocyte chemoattractant protein 1
(MCP-1) (also known as CCL2) and MCP-3 (also known as
CCL7), play a central role in the migration of Ly6C+ monocytes
from BM to blood. The number of these classical monocytes
was significantly decreased in the bloodstream, although it
was significantly higher in CCR2 knockout mice compared to
wild-type mice. Tsou et al. demonstrated that CCR2 ligands,
MCP-1 and MCP-7, are some of the most necessary chemokines
for proper control of monocyte levels (60). In addition, many
studies regarding CCR2 signaling and chemokines related to
Ly6C+ monocytes have been conducted for various diseases,
suggesting that classical monocytes play a pivotal role in immune
responses (61–64). By utilizing chromatin immunoprecipitation
sequencing and gene expression profiling, researchers revealed
that transcription factor KLF4 is a powerful indirect target
gene of interferon regulatory factor (IRF8) (65). In addition,
the differentiation of Ly6C+ monocytes was not observed
in IRF8−/− mice, suggesting that the IRF8-KLF4 axis is the
key modulator in monocyte development (65). Transcription
factor PU.1 (encoded by the Spi1 gene), one of the erythroblast
transformation–specific family transcription factors, is essential
for transcriptional regulation in the development of the
myeloid lineage (66). PU.1 is highly expressed in monocytes
and macrophages (67). During monopoiesis, PU.1 promotes
IRF8 expression in monocytic dendritic progenitors, whereas
IRF8 directly binds to the promoter region of the Klf4 gene
in common monocyte progenitors (cMoPs), resulting in
the differentiation of Ly6C+ monocytes (68). Hanna et al.
investigated nuclear receptor subfamily 4 group A member 1
(Nr4a1, Nur77) (69), and by analyzing the monocyte population,
they showed that Ly6C− monocytes exhibit apoptosis in the
BM of Nr4a1−/− mice. Additionally, as shown through a series
of adoptive transfer studies by Hanna et al., the conversion
of Nr4a1−/− Ly6C+ monocytes to Ly6C− monocytes is
aborted in the BM, blood, and tissues. This suggests that not
only is Nr4a1 vital for Ly6C− monocyte survival, but also
differentiation of Ly6C− monocytes from Ly6C+ monocytes
is also crucial (69). Regarding transcription factor CCAAT
enhancer–binding protein β (C/EBPβ), Mildner et al. confirmed
that the two monocyte subsets were originally homogenous
populations in the BM by transcriptome and epigenome
profiling assays. However, heterogeneity of Ly6Cint monocytes
in the blood, where the generation of Ly6C− monocytes arising
from Ly6C+ monocytes depends on C/EBPβ, is involved
in regulating Ly6C− monocyte survival factor Nr4a1 (70)
(Figure 1).
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FIGURE 1 | Monocyte development and mobilization. In the bone marrow (BM), pro-inflammatory Ly6C+ monocytes are derived from cMoPs that are differentiated
from a series of hematopoietic stem cells (HSCs) by transcription factors PU.1, interferon regulatory factor 8 (IRF8), and Kruppel-like factor 4 (KLF4). Ly6C+
monocytes emigrate out of the BM in a C-C chemokine receptor 2 (CCR2)-dependent manner, and the ligands of CCR2, C-C motif ligand 2 (CCL2) and C-C motif
ligand 7 (CCL7), stimulate Ly6C+ monocyte mobilization into the blood. The development of anti-inflammatory Ly6C− monocytes from Ly6C+ monocytes depends on
CCAAT enhancer–binding protein β (C/EBPβ)–dependent nuclear receptor subfamily 4 group A member 1 (NR4A1). Ly6C− monocytes crawling on the endothelium in
the periphery act in an immune surveillance capacity to maintain homeostasis.
FUNCTIONAL HETEROGENEITY OF
MONOCYTE SUBSETS IN MICE AND
HUMANS: THE VITAL ROLE OF MICRORNA
LEVEL DETECTION
Monocytes, which consist of leukocytes circulating through
the blood, are a heterogeneous population and a critical
component of an organism’s innate immune response against
inflammation (14, 71). Although murine monocytes are often
seen as dichotomous, monocytes in humans are divided
into three distinct subsets, which are differentiated by the
expression levels of CD14 (lipopolysaccharide receptor
complex component) and CD16 (FCγRIII immunoglobulin
receptor): (1) CD14++CD16− (classical), (2) CD14+CD16+
(intermediate), and (3) CD14+CD16++ (non-classical) (72).
When comparing murine and human monocytes, the classical
and non-classical monocytes in humans are analogous to
the Ly6C+ monocytes expressing CCR2highCX3CR1low and
Ly6C−CCR2lowCX3CR1high in mice (73). The third subset
of monocytes in humans, the intermediate monocytes, is not
comparable to any in mice and are thought to be in the middle
stage of classical monocytes transitioning into non-classical
monocytes (74, 75).
MicroRNAs (miRNAs), which are small non-coding RNAs,
bind to specific messenger RNAs (mRNAs) and inhibit the
translation or promote the degradation of mRNAs (76). They
play a vital role in regulating monocyte development and
function (77). From the extensive list of miRNAs, the miRNA
investigated first and foremost for monocytes is miRNA-146a,
which regulates the functional heterogeneity of monocyte subsets
(78) and shows the largest difference in expression levels
between Ly6C+ and Ly6C− monocytes. Steady-state expression
of miRNA146a is higher in Ly6C− monocytes than in Ly6C+
monocytes in mice. In addition, miRNA-146a depletion induces
abnormal myeloproliferation and myelodifferentiation of HSCs
(79) and augments the pro-inflammatory responses of Ly6C+
monocytes without affecting the change of monocyte subset
development (78). Through miRNome data analysis, differences
in miRNA expression were quantified between classical and
non-classical monocytes in humans. miRNA-17, miRNA-18a/b,
miRNA-19b, miRNA-20b, and miRNA-106a were overexpressed
in classical monocytes, whereas miRNA-132, miRNA-146a, and
miRNA-342-3p were overexpressed in non-classical monocytes
(80). Moreover, it was reported that different motility of
monocyte subsets (81) is associated with the expression of
miRNA-19a. Dang et al. showed that knockdown of miRNA-19a
markedly blocked themovement of CD16− monocytes, known as
classical monocytes, suggesting that miRNA-19a plays a crucial
role in promoting CD16− monocytes motility (82). Further
research also revealed that pre–miRNA-432 overexpression,
which is one of the miRNA candidates selected by in silico
analysis, induces apoptosis of CD16− monocytes, and the
expression of miRNA-432 was significantly different between
CD16− and CD16+ monocytes. This suggests that miRNA-432
regulates the apoptosis of CD16− monocyte. In addition, Zawada
et al. reported 38 miRNAs were differentially expressed in an
intermediate subset of monocytes in humans, among which
miRNA-150 was significantly downregulated in intermediate
monocytes compared with both classical and non-classical
monocyte subsets (83).
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Recently, Chipont et al. reported that the number of Ly6C−
monocytes in the blood, BM, and spleen is significantly
reduced in ApoE−/− miRNA-21–deficient mice, resulting in the
acceleration of the pro-inflammatory response in atherosclerosis.
The study suggests that miRNA-21 inhibition in monocytes
could be a plausible therapeutic approach in atherosclerosis
(84). In addition, Selimoglu-Buet et al. revealed that miRNA-
150 is a critical component in regulating the generation of
the Ly6C− monocyte subset in mice and humans (85). The
authors demonstrated that unrepressed expression levels of the
Tet methylcytosine dioxygenase 3 (Tet3) gene led to a decrease
in the levels of Ly6C− monocytes in miRNA-150–deficient
mice, highlighting the clinical implications that diminished
expression of miRNA-150 mostly found in the peripheral blood
CD14+ monocytes of patients with chronic myelomonocytic
leukemia. Given the studies discussed above, the detection of
various miRNA levels in monocytes is needed to expand our
knowledge of monocyte heterogeneity and develop new strategies
to ameliorate monocyte-related diseases (Table 1).
THE FUNCTION OF MICROGLIA AND
MONOCYTE-DERIVED MACROPHAGES:
THE IMPACT ON NEUROINFLAMMATION
FOLLOWING ISCHEMIC STROKE
Microglia
Microglia, or resident tissue macrophages in the central
nervous system (CNS), which account for 5 to 20% of the
glial cell population (86), contribute to tissue homeostasis by
interacting with neurons and surveilling the microenvironment
of the brain under a steady state (87). Upon an ischemic
cascade, microglia react to the danger signal and are rapidly
activated within minutes after the onset of ischemic stroke.
Following ischemic stroke, microglial proliferation peaks
between 2 and 3 days after the onset of the injury and lasts
for several weeks. Microglia are rapidly activated and can
phagocytose cell debris (clear apoptotic cells) (88). Activated
microglia have both beneficial and detrimental effects. From
the beneficial point of view, microglial depletion caused
by the administration of dual colony-stimulating factor 1
(CSF1)/c-kit inhibitor, PLX3397, may exacerbate post-ischemic
neuroinflammation in the brain. In mice, microglial depletion
can augment leukocyte infiltration, neuronal death, and
inflammatory mediators, including IL-1α, inducible NO
synthase, and TNF-α. This highlights that pathophysiological
exacerbation depends not only on lymphocytes and monocytes,
but also on inflammatory mediators and the action of
astrocytes (89). In addition, the selective elimination of
microglia results in significantly augmented infarct volume
after ischemic insult, indicating the positive function of
microglia (90). Moreover, minocycline treatment diminishes
polymorphonuclear cells and inhibits microglial activation,
which results in the attenuation of neuroinflammation in
the ischemic injured brain (91). Furthermore, microglial
depletion induced by liposome-encapsulated clodronate was
shown to accelerate inflammation and brain injury by a surge
of pro-inflammatory cytokines (e.g., IL-1β and TNF-α) and
chemokines (e.g., MCP-1 and MIP-1α) in an acute postnatal (day
7) ischemic model (92). This, in turn, indicates that microglial
contribution is a critical endogenous defense mechanism in
ischemic stroke.
On the other hand, the deleterious role of activated
microglia has also been reported. For example, microglia
are more prone to releasing cytotoxic factors, such as
ROS, NO, and TNF-α, in a severe ischemic environment
compared to a mild ischemic environment (93). Furthermore,
the preconditioning of isoflurane inhibits microglial
activation, thereby reducing the infarct volume and
attenuating neuronal apoptosis, supporting the detrimental
role of microglia in neuroinflammation after ischemic
stroke (94).
The copious amount of studies reporting controversial
theories regarding the role of microglia in ischemic stroke
reflects the importance of microglia and indicates the potential
of exploring new therapeutic strategies related to microglia.
Monocyte-Derived Macrophages
The process of monocytes homing in on inflamed tissue after
ischemic stroke is a vital response for host defense. Before
monocyte and leukocyte recruitment occurs at the injury site,
cytokine and chemokine levels increase, contributing to ischemic
stroke outcomes (95). After the onset of ischemic stroke,
monocytes circulating in the blood infiltrate into the brain
lesion through the disrupted blood–brain barrier (BBB) following
the leukocyte cascade as a result of neuroinflammation (96–
99). Monocyte infiltration is induced by several chemokines.
Many researchers have focused their studies on MCP-1, which
is also known as chemokine [C-C motif] ligand (CCL2)
(100, 101). CCL2 is a potent chemokine-specific recruiter
for monocytes, and its receptor, CCR2, is required for the
egress of classical monocytes to the bloodstream from the
BM. An increased level of circulating MCP-1 is associated
with increasing the long-term risk of ischemic stroke (102),
and the infiltration of CCR2+ monocytes is greatly diminished
in mice with dysfunctional CX3CR1-CCR2 signaling, resulting
in the attenuation of acute injury in a rodent model of
childhood stroke (61). CCR2 is highly associated with the
recruitment of pro-inflammatory monocytes to the ischemic
brain (103). However, Yang et al. showed that remote ischemic
limb conditioning (RLC) after ischemic stroke shifted peripheral
blood monocytes to the CCR2+ pro-inflammatory monocytes
subset, resulting in reduced acute brain infarct volume and
brain swelling and improved functional recovery (104). The
authors demonstrated that RLC-mediated protection against
ischemic stroke injury is disrupted by the adoptive transfer
of CCR2-deficient monocytes, highlighting the importance
of the RLC-induced shift of monocytes into the CCR2+
monocyte subset in attenuating ischemic stroke outcomes.
Recent studies have reported that long-term behavioral recovery
was exacerbated by blocking monocyte recruitment following
ischemic stroke in mice. To summarize, the number of
monocytes recruited to the ischemic hemisphere peaks 3 days
after stroke. Half of these infiltrating monocytes differentiate
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TABLE 1 | miRNAs-related monocyte heterogeneity.
Monocyte functions Pro-inflammatory Anti-inflammatory Anti-inflammatory
1. Heterogeneity of monocyte subsets related with miRNA expression in basal condition
Monocyte phenotype Human CD14++CD16− CD14+CD16+ CD14+CD16++
Mouse Ly6C+CCR2highCX3CR1low - Ly6C−CCR2lowCX3CR1high
















































2. Implications related to the role of miRNAs in monocyte subsets
miRNA-21 deletion Increase of pro-inflammatory response
miRNA-19a knockdown Inhibition of CD16− monocytes movement
miRNA-146a deletion Dysregulation of myeloproliferation and myelodifferentiation of HSCs
Dysregulation of pro-inflammatory response
miRNA-150 deletion Decrease of Ly6C− monocyte by overexpression of Tet3 gene
miRNA-432 overexpression Increase of CD16− monocyte apoptosis
into pro-inflammatory macrophages (M1), whereas the other
half exhibit an anti-inflammatory macrophage (M2) phenotype.
However, treatment with CCR2 antibody, MC-21, drastically
decreases the expression of anti-inflammatory genes, resulting
in the abolishment of long-term behavioral recovery (105). In
the same context, monocyte/macrophage deletion increases the
M1/M2 polarization ratio of microglia, aggravating the ischemic
stroke injury. These results indicate that infiltrating monocyte-
derived macrophages may regulate microglial polarization by
shifting excessive pro-inflammatory M1 polarization to the M2
restorative process of microglia (106).
It has been generalized that once resident microglia and
infiltrating monocytes turn into macrophages in response to
ischemic injury, it is hard to differentiate the origins of the
macrophages, as they are morphologically similar (107). To
overcome this matter, Tanaka et al. conducted a series of
experiments in tracing monocytes/macrophages derived from
BM. Chimeric mice expressed enhanced green fluorescent
protein in a cerebral ischemic environment, revealing differences
in the exact roles of resident microglia and monocyte-derived
macrophages (108).
Meanwhile, in addition to the CCR2-CCL2 axis, another
chemokine axis pertaining to monocytes in ischemic stroke has
been reported. C-C motif ligand 5 (CCL5) inhibition induced
by the addition of MKEY, an antagonist of CXCL4-CCL5
heterodimer formation, was shown to significantly reduce the
infiltration of Ly6C+ monocytes, resulting in the attenuation of
classical monocyte-mediated neuroinflammation in a model of
experimental ischemic stroke (109). Moreover, repetitive hypoxic
preconditioning prior to the onset of ischemic stroke, which
induces upregulated CXCL12 levels, blocks leukocyte infiltration,
thereby endogenously contributing to an anti-inflammatory
phenotype (110). In contrast to Ly6C+ monocytes, Ly6C−
alternative monocytes have a different path of infiltration.
CX3CR1 ligand fractalkine (CX3CL1), which is expressed in
endothelial and neuronal cells (111), interacts with Ly6C−
monocytes that are patrolling the vasculature (112) and
microglia that are surveilling the CNS environment. Both
Ly6C− monocytes and microglia highly express its receptor,
CX3CR1 (113), under physiological conditions. At the onset
of ischemic stroke, these interactions are disrupted, and as the
level of CX3CL1 abnormally increases, Ly6C− monocytes rapidly
infiltrate the brain parenchyma (114), leading to microglial
activation. The regulation of transforming growth factor β-
activated kinase 1 (TAK1), which is involved in both innate and
adaptive immune responses and has conflicting inflammatory
effects depending on the cell type, plays a key role in
monocyte infiltration into the injury site following ischemic
stroke. TAK1 deletion leads to reduced monocyte infiltration,
thereby improving outcomes after ischemic stroke (115). In
addition, Werner et al. demonstrated that CXC motif chemokine
receptor 4 (CXCR4) deficiency diminishes monocyte infiltration
and dampens the levels of pattern recognition and defense
response gene expression in monocyte-derived macrophages at
the ischemic injury site, resulting in deteriorated ischemic stroke
outcomes. These results indicate that CXCR4 distinguishing
HSC-derived monocytes from microglia is a crucial factor in
sustaining the beneficial role of monocytes through an innate
immune system against neuroinflammation following ischemic
stroke (116).
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CONVERSION OF MONOCYTES AFTER
ISCHEMIC STROKE
There has recently been a surge in interest regarding the origin
of Ly6C− macrophages. Early-infiltrating pro-inflammatory
monocytes can differentiate into anti-inflammatory Ly6C−
wound macrophages (MONO to MØ) after ischemic stroke
(117). In addition, CCR2highCX3CR1low pro-inflammatory
monocytes have been shown to turn into CCR2lowCX3CR1high
anti-inflammatory macrophages (MONO to MØ) 3 days
after ischemic stroke in CX3CR1gfp/+−CCR2rfp/+ functional
transgenic mice using two-photon intravital imaging, indicating
that monocytes play a notable role in neuroinflammation
following ischemic stroke (118).
Recently, the originally proposed dogma has been challenged
in regard to the role of monocytes and monocytes differentiating
into macrophages in the immune response. Jakubzick et al.
revealed through parabiosis and bromodeoxyuridine pulse-chase
analysis that monocytes can enter tissues and transmigrate to
lymph nodes, maintaining their markers as monocytes, while
not expressing macrophage or dendritic cell (DC) markers.
In other words, classical monocytes are able to minimally
differentiate into macrophages or DCs, surveying the non-
lymphoid tissue and transporting antigens to lymph nodes under
a steady state (119). However, this new concept of monocytes
(MONO to MONO) has not been observed in the ischemic
stroke environment (Figure 2). Future studies are warranted to
examine whether the MONO-to-MONO conversion occurs after
ischemic stroke.
MONOCYTE BIOMARKERS IN CLINICAL
STUDIES OF ISCHEMIC STROKE
Abundant data have been accumulated regarding the overall
pathologies of ischemic stroke. Based on these data, novel
therapies, such as tissue plasminogen activator (tPA), are used
to treat ischemic stroke. However, because several factors, such
as sex, age, duration of ischemia, localization of the infarction,
and possible comorbidities, must be evaluated for accurate
ischemic stroke diagnosis, the treatments available today, such
as thrombolytic agents, may only be effective for a narrow
range of patients. Moreover, ischemic stroke is not a single
neurodisease that leads to a local immune response; rather, it
is a systemic inflammatory response that involves immune cells
in the blood, making it more complicated to treat. To untangle
and understand the complex systemic inflammatory response
that follows ischemic stroke, monocytes are a popular research
topic in the vast field of stroke. Today, the standard treatment
for acute ischemic stroke (AIS) is thrombolytic therapy, which
breaks down blood clots to restore blood flow in the brain
(120). However, there are limitations to this treatment method,
as it is only effective when the treatment is received within 3
to 4.5 h of symptom onset (121). As there is a narrow time
frame for this therapeutic method, many patients are left with
no alternative option. Therefore, much effort has been devoted
to research new therapeutic methods to prevent the unfortunate
outcomes of stroke (122, 123). To discover novel methods of
ischemic stroke therapy, factors related to inflammation in the
brain, such as C-reactive protein (CRP) (124), hepatocyte growth
factor (125), insulin-like growth factor-1 (IGF-1), IGF-binding
protein-3 (126), factor XIII (127), brain-derived neurotrophic
factor (128), and D-dimer (129), have been investigated.
In addition, research on newly identified prognostic
biomarkers related to monocytes in AIS has gained interest.
Recently, Liu et al. reported that a higher monocyte-to-high-
density lipoprotein ratio (MHR) is highly associated with the
risk of poor functional outcomes within 3 months in patients
with AIS, thereby suggesting MHR as a novel marker to evaluate
ischemic stroke prognosis, widening the treatment window
from mere hours to months (130). Wang et al. demonstrated
the correlation between macrophage migration inhibitory factor
(MIF) serum levels and ischemic stroke, stating that high MIF
levels are directly related to moderate or severe ischemic stroke
outcomes (131). Another emerging prognostic biomarker for
AIS is the lymphocyte-to-monocyte ratio (LMR) (132). In a
clinical study, Ren et al. assessed the stroke severity of 512
patients with AIS and 3 month outcomes using the National
Institute of Health Stroke Scale (NIHSS) and conducted a series
of experiments to evaluate relevant AIS markers, showing that
a lower LMR is closely associated with severe AIS and poor
outcomes. Similarly, a lower LMR is independently related to
higher risk of hemorrhagic transformation (HT) in patients with
AIS (133), suggesting that the LMR upon admission has good
predictive value for AIS prognosis and may be used as a predictor
for HT.
It has also been reported that T-cell immunoglobulin
and mucin domain (TIM-4) expression levels in monocytes
are remarkably elevated in patients with AIS after 2 and
5 days when compared to control patients. Importantly,
TIM-4 expression levels in non-classical monocytes are
highly correlated with NIHSS scores 2 days after stroke
and are significantly increased in patients with AIS and
poor outcomes, suggesting that the percentage of TIM-4
expression in non-classical monocytes could be a biomarker
in predicting the clinical course and prognosis in AIS (134)
(Table 2). In summary, numerous studies on biomarkers
for the detection of ischemic stroke have been actively
conducted in clinical practice; however, more work is needed
to identify monocytes as a novel predictor of ischemic stroke.
Therefore, research to discover biomarkers related to monocytes






At present, there is no effective therapy against ischemic
stroke and its sequelae. A variety of proteins have been
studied (135) to confirm accurate ischemic stroke diagnosis
and mitigate the neuroinflammation following ischemic
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FIGURE 2 | Ly6C+ pro-inflammatory monocyte conversion and contribution to ischemic stroke recovery in vivo. After the onset of ischemic stroke, DAMP released by
dying neurons activates microglia and astrocytes. C-C motif ligand 2 (CCL2) and C-C motif ligand 5 (CCL5), which are secreted by activated microglia and astrocytes,
induce the infiltration of Ly6C+ pro-inflammatory monocytes into the injury site. Infiltrating Ly6C+ monocytes convert into M2 macrophages depending on the
presence of Nr4a1 (MONO to MØ). In addition, activated microglia are polarized into M2 macrophages, releasing anti-inflammatory cytokines, resulting in ischemic
stroke recovery. However, whether the conversion of Ly6C+ pro-inflammatory monocytes to Ly6C− anti-inflammatory monocytes (MONO to MONO) occurs in the
brain, attenuating neuroinflammation following ischemic stroke, remains unclear.
stroke. Despite these efforts, successful therapeutics that are
applicable to clinical studies regarding ischemic stroke have not
been investigated.
Studies have recently been conducted in the field of stroke
regarding the use of RNA in peripheral blood (136). These studies
are supported by clinical applications in the diagnosis of diseases,
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TABLE 2 | Monocyte-related biomarkers of acute ischemic stroke (AIS) outcomes.
Biomarkers Biomarker levels indicating severe AIS *OR/**(r) P-value References
MHR High 2.58* 0.015 (130)
MIF High 1.06* <0.01 (131)
LMR Low 0.523* 0.029 (133)
TIM-4 High 0.351** 0.048 (134)
AIS, acute ischemic stroke; LMR, lymphocyte-to-monocyte ratio; MHR, monocyte-to-high-density lipoprotein ratio; MIF, macrophage migration inhibitory factor; TIM-4, T-cell
immunoglobulin and mucin domain-4. *OR, odds ratio; **r, correlative coefficient.
such as myocardial infarction (137) and cancer (138). Brain
transcriptomic analysis has been used in many experimental
ischemic stroke studies to investigate specific changes in gene
expression. These studies were mostly conducted in rodent
models of ischemic stroke (139). As simultaneous blood and
brain transcriptomics in patients with ischemic stroke is not
feasible, Ramsay et al. conducted a series of experiments to
analyze the whole gene expression pattern in both the blood
and brain after ischemic stroke in a primate stroke model using
Rhesus macaque (140).
Monocytes and macrophages infiltrate the ischemic injured
brain and significantly impact ischemic stroke outcomes
by regulating neuroinflammation. Hence, to investigate the
exact role of monocytes and macrophages after ischemic
stroke, current research trends have focused on transcriptome
profiling (141).
Recently, Wang et al. performed genome-wide transcriptome
profiling using RNA sequencing (RNA-seq) of monocytes
and macrophages in the blood and brain samples of an
ischemic stroke rodent model with distal middle cerebral
artery occlusion (dMCAO) (142). Their findings indicated
that ischemic stroke induced significant transcriptome changes
in monocytes and macrophages in the post-stroke brain;
however, only moderate changes were observed in the blood
samples of the ischemic stroke group when compared with the
control group. Further, macrophages in the post-ischemic stroke
brain display unique transcriptome characteristics, robustly
favoring neurovascular plasticity 5 days after ischemic stroke,
suggesting that macrophages in the brain upregulate genes
related with neovascularization, such as oncostatin M (Osm)
(143), osteopontin (Spp1) (144), growth differentiation factor 15
(GDF15) (145), vascular endothelial growth factor (VEGF) (146),
and fibroblast growth factor 1 (FGF1) (147). Surprisingly, lower
angiogenesis and neurogenesis were verified in myeloid cell–
specific peroxisome proliferator-activated receptor γ (PPARγ)
knockout (mKO) mice than in wild-type mice 5 days after
ischemic stroke. These results suggest that PPARγ, a master
regulator of monocyte/macrophage genomic reprogramming, is
a novel therapeutic target in determining reparative macrophage
phenotypes and improving neurological function following
ischemic stroke (142).
Another study by Zhang et al. revealed that PPARγ and
signal transducer and activator of transcription 6 (STAT6) are
potential upstream regulators of efferocytosis-related genes in
macrophages, driving pro-efferocytic and anti-inflammatory
phenotypes in the brain, thereby promoting ischemic stroke
injury and recovery (148). To summarize, the blood-borne
infiltrating monocyte/macrophage population, which is
phenotypically expressed as CD11c-Ly6G−CD11b+CD45high
sorted by FACS in the brain, upregulates genes related with
phagocytic activities, such as triggering receptor expressed
on myeloid cells-1 (TREM1) (149) and extracellular signal–
regulated kinase 5 (ERK5) (150), 5 days after dMCAO. In
addition, genes involved in recruiting phagocytes, such as those
encoding purinergic receptor 2 (P2Y2) and S1P receptor (S1PR1),
were remarkably upregulated in brain monocytes/macrophages
when compared with blood monocytes 5 days after dMCAO.
Additionally, genes participating in the engulfment of apoptotic
cells, such as Abca1, Prkaca, and Rac1, and representative
cytoskeletal regulators (Phldb2, Stmn1, Cit, Rac1, Cttn, Aurka,
and Baiap2) were significantly upregulated in brain macrophages
compared with blood monocytes, suggesting that active
engulfment signaling and cytoskeletal rearrangement in brain
macrophages occur 5 days after dMCAO. Importantly, according
to upstream regulator analysis, PPARγ and STAT6 may play
pivotal roles in determining the pro-efferocytic transcriptome
of macrophages in the brain 5 days after ischemic stroke (148).
Regarding the transcriptome profiling, although the results
could expand our knowledge of the exact role of monocytes and
macrophages in the cerebral ischemic environment, the findings
do not generalize all cases of ischemic stroke, as the results were
only obtained from a single time point 5 days after ischemic
stroke. Therefore, future studies may be warranted to confirm
and examine the temporal profile of monocyte/macrophage
genomic changes.
ANTI-INFLAMMATORY DRUGS RELATED
TO MONOCYTES AND MACROPHAGES
FOR TREATMENT OF ISCHEMIC STROKE
Until recently, inflammatory monocytes recruited to the
brain were believed to be representative mediators of
neuroinflammatory injury and secondary neurotoxicity
after ischemic stroke. Therefore, therapeutic intervention
targeting CCR2 to prevent the recruitment of pro-inflammatory
monocytes was considered to be beneficial against ischemic
stroke, even though available data were controversial regarding
monocytes roles after ischemic stroke (151, 152). These
controversial aspects of monocytes were totally dependent on
Frontiers in Neurology | www.frontiersin.org 8 October 2020 | Volume 11 | Article 578003
Park et al. Monocyte Transmodulation for Ischemic Stroke
the severity and time window of the ischemic stroke, which
suggested the importance of new therapeutics that could
modulate the activity of monocytes in ischemic stroke. Current
ischemic stroke treatments are focused on anti-inflammatory
strategies that convert the complex characteristics of monocytes
into anti-inflammatory proprieties following ischemic stroke.
Aspirin is a non-selective cyclooxygenase inhibitor that can
prevent macrophage accumulation, resulting in cerebrovascular
protection in the model of stroke-prone spontaneously
hypertensive rats (SHRSP) (153). It has also been reported that
aspirin delays the onset of ischemic stroke (153), providing
clinical proofs of its protective effect against stroke in humans
(154). Further, rosuvastatin, a widely used statin for lowering
cholesterol and high-sensitivity CRP (155, 156), showed to
attenuate the transcription of inflammatory biomarkers, such as
MCP-1, IL-1β, TNF-α, TGF-β1, and p-selectin, while increasing
the mRNA of endothelial NO synthase, overall supporting
the anti-inflammatory processes in stroke-prone rats (157).
Although it was reported that the use of statins is associated
with augmented occurrences of hemorrhagic stroke in patients
with a clinical history of cerebrovascular disease, they can be
beneficial in preventing ischemic stroke (158). In the preclinical
systematic review conducted by White et al., the PPARγ agonists
thiazolidinediones, including rosiglitazone and pioglitazone,
were found to suppress the cyclooxygenase-2 expression and
promote the PPARγ DNA binding, resulting in the inhibition
of inflammation after ischemic stroke (159). In addition,
Nakamura et al. demonstrated that pioglitazone inhibits the
infiltration of macrophages and suppresses the expression of
inflammatory cytokines such as MCP-1 and TNF-α, thereby
exerting a neuroprotective effect in SHRSP (160). Another
anti-inflammatory drug targeting microglia and macrophages is
minocycline, a known semisynthetic tetracycline antibiotic with
antiapoptotic properties. It was demonstrated that minocycline
inhibits activated microglia/macrophages that are involved in
the demise of neurons and astrocytes, as well as endothelial
cells in neurological diseases (161, 162). Evidence supporting
the anti-inflammatory effect of minocycline showed that early
treatment with this drug reduces the number of activated
microglia/macrophage in the peri-infarct lesion of the ischemic
injured brain, resulting in improved neurological outcomes after
ischemic stroke in rats (163) (Table 3).
From the strategies of ischemic stroke treatment currently
available, the best therapeutic approach in the acute phase is
thrombolysis with tPA; however, the therapeutic time window is
extremely narrow (<4.5 h within stroke onset) (164). To expand
the therapeutic window and, consequently, reach more patients
with ischemic stroke, recent studies have focused on investigating
immune cell–targeted therapies, such as anti-inflammatory drugs
that are fundamentally non-invasive and effective approaches
for ischemic stroke prevention (165). Despite substantial efforts
to find an effective treatment for ischemic stroke through
pharmacological modulation of immune cells, this still remains
a challenge. As inflammatory mechanisms following ischemic
stroke are complex, with multiple deleterious and protective
effects, recent clinical trials of immunological therapies have
failed (166–168). Importantly, most in vitro and in vivo studies
regarding ischemic stroke were performed at the level of a single
disease, not including comorbidities, such as hyperglycemia or
diabetes. It was reported that most patients with stroke have
comorbidities (169). Therefore, future studies should address
ischemic stroke using models that mimic the disease, as well as
its comorbidities, similar to patients, in order to develop more
specific and accurate therapeutics.
As outlined above, recent emerging targets of monocytes
transmodulation for ischemic stroke treatment have been focused
on two factors, Nr4a1 and PPARγ (170, 171). As a vital factor for
survival of non-classical monocytes, Nr4a1 plays an important
role in the differentiation of Ly6C+ monocytes toward the
anti-inflammatory phenotype of M2 macrophages, which has
been proven in defective myocardial remodeling studies using
Nr4a1−/− mice (172). Furthermore, monocytes/macrophages
polarization against neuroinflammation via pharmacological
PPARγ activation in hyperglycemic and PPARγ (KO) mice
resulted in brain repair with neovascularization in the infarct
border zone after ischemic stroke. These findings suggest
that Nr4a1 and PPARγ are strong modulators of Ly6C+
monocytes toward anti-inflammatory macrophage polarization,
without affecting the infiltration of monocytes into the injured
brain tissue.
Past studies have intensively researched whether the
infiltration of CCR2+ inflammatory monocyte or inhibition of
CCR2 expression on monocytes affects post-ischemic stroke.
Moreover, the role of inflammatory monocytes is known to
vary in a time-dependent manner. Therefore, future therapeutic
strategies may need to focus on increasing the polarization of
infiltrating monocytes into macrophages with anti-inflammatory
properties (M2) through modulation of factors such as Nr4a1,
PPARγ, and miRNAs (e.g., miRNA-21, miRNA-146a) (Figure 3).




Numerous studies in preclinical and clinical trials aim to
discover functional recovery after ischemic stroke. From this
point of view, immunoregulation by pharmacological drugs
and neurogenesis stimulation, such as stem cell transplantation,
have been considered as pivotal mechanisms in ischemic
stroke treatment. However, despite these tremendous efforts to
overcome ischemic stroke, no clear approaches for ischemic
stroke therapy have been validated until now. With the recent
advancements in science, various research regarding treatments
of ischemic stroke using various cutting-edge technologies have
been reported (Figure 4).
CRISPR/Cas9 System
Clustered regularly interspaced short palindromic repeats
(CRISPR)/Cas9 genome editing has emerged as a powerful
tool that enables the correction of DNA mutation in both in
vitro and in vivo models. CRISPR/Cas9 system is also known
to be effective in creating gene KO and knock-in animal
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TABLE 3 | Current ischemic stroke therapeutics targeting anti-inflammation.
Therapeutics Role(s) Effect(s) on stroke
Aspirin - Non-selective cyclooxygenase inhibitor - Decrease the accumulation of macrophages
- Delays the onset of ischemic stroke
Rosuvastatin - Lowers low-density lipoprotein cholesterol
- Lowers high-sensitivity CRP levels
- Attenuate the expression of inflammatory
biomarkers: MCP-1, IL-1β
TNF-α, TGF-β1, p-selectin
Thiazolidinediones - PPARγ agonists - Suppress the cyclooxygenase-2 expression
- Inhibit the infiltration of macrophages
- Decrease the expression level of MCP-1 and TNF-α
- Promote the PPARγ DNA binding
Minocycline - Semisynthetic tetracycline antibiotic - Reduce the microglia/macrophage activation
- Improves the neurological outcome
FIGURE 3 | Immunotherapeutic strategy through the modulation of monocytes following ischemic stroke.
FIGURE 4 | Current advanced biotechnologies for treatment of ischemic stroke.
models for investigating the biological and pathophysiological
mechanisms in various diseases (173). Recently, studies applying
the advantages of CRISPR/Cas9 system have been reported in
the field of stroke. It has been reported that the inhibition
of semaphorin 4D (Sema4D), an axon guidance molecule,
and its receptor, PlexinB1, which has the highest affinity
to Sema4D, remarkably attenuate the inflammatory responses
and BBB permeability and significantly reduce the infarct
volume, resulting in the improvement of ischemic stroke
outcome. The researchers in the study provided decisive evidence
demonstrating the effect of Sema4D/PlexinB1 signaling using
lentiviral transfection system targeting PlexinB1 disruption
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through CRISPR gene editing, which suggests that the regulation
of Sema4D/PlexinB1 signaling is a novel therapeutic target for
acute-phase treatment of ischemic stroke (174). Another study
using CRISPR/Cas9 system in a genetic approach has been
reported. Li et al. demonstrated that neuronal apoptosis was
highly protected through Akt activation in ischemia-reperfusion
(I/R) injury in Tollip-deficient rats, suggesting that Tollip is a
novel modulator of I/R injury by promoting neuronal apoptosis
and neuroinflammation (175). So far, despite the numerous
advancements made through various genetic manipulations
regarding the potential treatments of ischemic stroke, treatments
targeting monocyte transmodulation using CRISPR/Cas9 system
have not yet been reported. Therefore, future research to
overcome this matter would be needed to continue as it may lead
to more promising ischemic stroke treatment.
Applied Nanotechnologies
As ischemic stroke occurs through different etiologies and
pathophysiologies, the evolution of damage is complex and
dynamic. Technologies based on structural and molecular brain
imaging and effective drug delivery are necessary to apply
precise and appropriate treatments at different phases. As a
result, nanotechnologies, which involve nanomaterials, such as
liposomes, nanocapsules, nanotubes, and micelles, have been
developed for the treatment of stroke (176). Furthermore, to
accurately assess a prognosis and overcome the difficulties
limiting the present treatment of ischemic stroke, efforts to
develop new biomarkers and investigate factors related to
monocytes following ischemic stroke are ongoing in clinical
studies. Recently, new assessments have been applied in clinical
studies to improve the outcomes of ischemic stroke. Hou
et al. reported the results of a new trial that showed that
using monocytes and neutrophils, which were developed as
carriers for cRGD [cyclo (Arg-Gly-Asp-D-Tyr-Lys)] liposome-
mediated drug delivery, may alleviate ischemic stroke outcomes
(177). Targeting monocyte that protects neuronal cell death
through nanotechnology could be a novel therapeutic strategy for
ischemic stroke. However, few optimal “nano” -related studies
regarding immunomodulation of monocytes in ischemic stroke
have been reported yet. Future studies are warranted to resolve
the complexity of ischemic stroke in the context of nanotherapy
targeting monocytes.
Three-Dimensional Bioprinting
The main goal of ischemic stroke treatment is to promote the
neurogenesis and angiogenesis, thereby improving the functional
outcomes. However, few patients with ischemic stroke onset can
be served timely with thrombolytic treatment, which mainly
focuses on the rapid reperfusion, from the acute phase of
occlusion. Therefore, to overcome the limitations, strategies
ultimately promoting neurorecovery have been investigated
(178). As a part of these therapeutic strategies, bioprinting,
an emerging modern technology mixing cells related with
tissue regeneration, such as stem cells, with biomaterials that
are designed with high precision in order to obtain high
compatibility with host tissues, has been developed (179, 180).
Recently, it was reported that implanted exogenous human
neural progenitor cells, which are electrically preconditioned
on a conductive biopolymer scaffold prior to transplantation,
cause the endogenous vasculature changes that enhance the
gene expression involved in VEGF-A pathway, resulting in
improvement of functional recovery after ischemic stroke (181).
In addition, Brzezinski et al. demonstrated the efficacy of 3D
printed novel holdfast devices. Briefly, left atrial appendage
(LAA) occlusion is used as a method of preventing ischemic
stroke in patients with atrial fibrillation. LAA exclusion device
based on 3D printing using the selective laser sintering
technology with polyamide powder was tested in this research
because of its broad accessibility and low costs for production.
The researchers tested for the reactions with local tissue and
biocompatibility of the device when implanted in swine models.
Results showed no clots on the atrium surface, and the foreign
body reaction levels were similar to that of a polyester graft.
This novel device that was evaluated in the research meets the
biocompatibility parameters without any issues; that is, it is a
suitable device for stroke prevention (182).
CONCLUSION
During the past decade, significant progress has been achieved
in the understanding and treatment of ischemic stroke.
In particular, many studies have investigated the role of
monocytes from various angles, including cellular and
genetic approaches. The evidence discussed here suggests
that the application of transcriptomics and epigenomics
targeting monocyte/macrophage plays a crucial role in the
regulation of neuroinflammation following ischemic stroke.
The advancements in proteomics have remarkably contributed
to development of novel biomarkers related to monocytes in
evaluating the prognosis of ischemic stroke in clinical studies.
The role of infiltrating monocytes in ischemic stroke is still
controversial as it varies depending on timing and the degree
of damage. This conflicting discussion supports vital evidence
related to the importance of monocytes and the potential to
convert into beneficial M2 macrophages by transmodulation.
Several studies related to Ly6C− alternative monocytes have
also been reported in the field of ischemic stroke. Therefore,
further research regarding alternative monocytes and the
transmodulation of classical monocytes with the application
of advanced biotechnologies is necessary, as it may open
doors to new therapeutic strategies for stroke. Taken together,
immunomodulation that aims to specifically control the
functions of each monocyte subset is a curtail strategy for
developing new therapies and may provide a promising future
for the treatment of ischemic stroke.
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GLOSSARY
AIS, acute ischemic stroke; BBB, blood–brain barrier; BM,
bone marrow; BrdU, bromodeoxyuridine; CCL2, chemokine [C-
C motif] ligand 2; CCL7, chemokine [C-C motif] ligand 7;
CCR2, C-C chemokine receptor 2; cMoP, common monocyte
progenitors; CNS, central nervous system; CRP, C-reactive
protein; CX3CL1, C-X3-C motif chemokine ligand 1; CX3CR1,
C-X3-C motif chemokine receptor 1; CXCR4, C-X-C motif
chemokine receptor 4; DCs, dendritic cell; dMCAO, distal middle
cerebral artery occlusion; ERK5, extracellular signal–regulated
kinase 5; FGF1, fibroblast growth factor 1; HSCs, hematopoietic
stem cells; HT–hemorrhagic transformation; IGF-1, insulin-like
growth factor-1; IL-10, interleukin 10; IL-13, interleukin 13;
IL-1b, interleukin-1β; IL-4, interleukin-4; IL-6, interleukin-6;
IRF8, interferon-regulatory factor 8; KLF4, kruppel-like factor 4;
LMR, lymphocyte-to-monocyte ratio; Ly6C, lymphocyte antigen
6C; M-CSF, macrophage colony stimulating factor; MCP-1,
monocyte chemoattractant protein-1; MHR, monocyte-to-high-
density lipoprotein ratio; MIF, migration inhibitory factor;
mKO, myeloid cell-specific PPARγ knockout; NIHSS, national
institute of health stroke scale; NO, nitric oxide; NR4A1, nuclear
receptor subfamily 4 group A member 1; Osm, oncostatin
M; PPARγ, peroxisome proliferator-activated receptor γ; RLC,
remote ischemic limb conditioning; ROS, reactive oxygen
species; S1PR1, S1P receptor 1; STAT6, signal transducer and
activator of transcription 6; TAK1, transforming growth factor-
β-activated kinase 1; Tet3, Tet methylcytosine dioxygenase; TIM-
4, T-cell immunoglobulin and mucin domain-4; TNF-α, tumor
necrosis factor-α; tPA, tissue plasminogen activator; TREM1,
triggering receptor expressed on myeloid cells 1; VEGF, vascular
endothelial growth factor.
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